Coloplast A/S Highlights Strong Performance in Recent Fiscal Year
Coloplast A/S has reported impressive achievements for the fiscal year 2024/25, showcasing significant growth and a firm focus on sustainability. The company experienced an organic growth of 7%, with EBIT margins reaching 28%. Reported revenue surged by 3%, totalling DKK 27,874 million.
To delve deeper, here’s a breakdown of the growth across various business segments: Ostomy Care grew by 6%, Continence Care by 8%, Voice & Respiratory Care by 9%, Wound & Tissue Repair by 8%, and Interventional Urology saw a modest 2% increase. This expansion reflects Coloplast's commitment to enhancing healthcare solutions.
Financial Performance and Key Metrics
The EBIT for Coloplast was reported at DKK 7,670 million, marking a 5% rise from the previous year. The EBIT margin showed notable improvement, up from 27% last year to 28%. Adjusted net profit before special items also rose, hitting DKK 5,148 million, which is an increase of DKK 123 million compared to last year, with adjusted diluted earnings per share climbing to DKK 22.84.
Additionally, special items expenses amounted to DKK 469 million, which are linked to profitability initiatives, including the divestment of the Skin Care line and management restructuring efforts. The company's return on invested capital (ROIC), adjusted for these special items, remained strong at 15%, consistent with last year's performance.
Dividends and Shareholder Returns
Coloplast has shown its dedication to returning value to shareholders through dividends. The Board of Directors has recommended a final dividend of DKK 18.00 per share, contributing to a total dividend of DKK 23.00 per share for the year, which is an increase from DKK 22.00 last year. This reflects the company's robust financial health and its commitment to rewarding its investors.
Focus on Sustainability and Operational Efficiency
In addition to its financial success, Coloplast has made remarkable strides in sustainability efforts. The company achieved a production waste recycling rate of 83% during the fiscal year, surpassing its 2025 goal of 75%. This remarkable performance was primarily due to effective partnerships with local recycling manufacturers at operational sites in Hungary and Costa Rica.
Moreover, the company has reduced its scope 1 and 2 emissions by 41% compared to the base year 2018/19, a significant improvement over the 22% reduction reported last year. This reduction is mainly attributed to the transition away from natural gas usage and enhancements in energy efficiency throughout the organization.
Health and Safety Initiatives
Coloplast has not only focused on environmental sustainability but has also prioritized employee health and safety. The company reported a decrease in lost time injury frequency to 1.7 ppm for FY 2024/25, down from 2.1 ppm in the prior year, demonstrating its commitment to a safer work environment.
Future Guidance for FY 2025/26
Looking ahead, Coloplast A/S anticipates continued growth, projecting around 7% organic revenue growth and an EBIT growth rate of the same percentage in constant currencies for FY 2025/26. The expected return on invested capital is around 16%, indicating a positive trajectory for the company.
The company's optimistic outlook is built on the assumption of sustained momentum in its Chronic Care business and improved performance in Acute Care. While reported growth in DKK is forecasted between 4-5%, the company is preparing for potential negative impacts from currency fluctuations and its recent divestment activities.
Investment and Strategic Development
In line with its Impact4 strategy, Coloplast aims to stabilize EBIT growth despite anticipated costs linked to inflation and production ramp-ups. The management's focus remains on enhancing the EBIT margin to around 20%, driving operational efficiency through strategic investments.
Frequently Asked Questions
What were the key highlights of Coloplast's FY 2024/25 report?
Coloplast reported a 7% organic growth, with EBIT margins at 28%, along with a total revenue of DKK 27,874 million.
What is Coloplast's dividend for the year?
The Board has recommended a year-end dividend of DKK 18.00 per share, bringing the total dividend to DKK 23.00 for the year.
How is Coloplast performing in terms of sustainability?
The company achieved an 83% production waste recycling rate and reduced scope 1 and 2 emissions by 41% compared to the base year 2018/19.
What is the expected growth for FY 2025/26?
Coloplast anticipates around 7% organic revenue growth and EBIT growth for FY 2025/26, aiming for a return on invested capital of approximately 16%.
Who can I contact for more information about Coloplast?
For investor inquiries, you can contact Anders Lonning-Skovgaard, CFO, or Kristine Husted Munk, Senior Director of Investor Relations at their provided contact numbers.
